Tuomikoski P¹, Salomaa V², Havulinna A², Airaksinen J³, Ketonen M⁴, Koukkunen H⁵, Ukkola O⁶, Kesäniemi YA⁶, Lyytinen H¹, Ylikorkala O¹, Mikkola TS⁷.

Author information

Abstract

OBJECTIVES:

The role of postmenopausal hormone therapy (HT) in the incidence of acute coronary syndrome (ACS) has been studied extensively, but less is known of the impact of HT on the mortality risk due to an ACS.

STUDY DESIGN AND MAIN OUTCOME MEASURES:

We extracted from a population-based ACS register, FINAMI, 7258 postmenopausal women with the first ACS. These data were combined with HT use data from the National Drug Reimbursement Register; 625 patients (9%) had used various HT regimens. The death risks due to ACS before admission to hospital, 2-28, or 29-365days after the incident ACS were compared between HT users and non-users with logistic regression analyses.

RESULTS:

In all follow-up time points, the ACS death risks in HT ever-users were smaller compared to non-users. Of women with HT ever use, 42% died within one year as compared with 52% of non-users (OR 0.62, p<0.001). Most deaths (84%) occurred within 28days after the ACS, and in this group 36% of women with ever use of HT (OR 0.73, p=0.002) and 30% of women with ≥5year HT use (OR 0.54, p<0.001) died as compared to 43% of the non-users. Age ≤60 or >60 years at the HT initiation was accompanied with similar reductions in ACS mortality risk.

CONCLUSIONS:

Postmenopausal HT use is accompanied with reduced mortality risk after primary ACS.

Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

KEYWORDS:

Case fatality; Estrogen; Myocardial infarction

PMID: 27823727
DOI: 10.1016/j.maturitas.2016.09.015

資料來源：PubMed